ST-elevation Myocardial Infarction (STEMI)
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Verona PharmaUK - London
1 programMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
Verona PharmaMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Clinical Trials (1)
NCT06965023Verona PharmaMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Start: Apr 2025Est. completion: Dec 2027
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
1 companies competing in this space